Pfizer, Allergan terminate merger after U.S. targets tax loophole

Andrew V. Pestano
WASHINGTON, April 6 (UPI) -- Pfizer and Allergan have abandoned a $152 billion merger due to U.S. government actions attempting to close a tax loophole known as corporate inversions.